Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 7 (5) , 723-731
Abstract
Background—: We aim to identify and quantify the value of biomarkers for incident new-onset heart failure (HF) in a community-based cohort and subgroups based on cardiovascular risk and evaluate the prognostic value of 13 biomarkers for HF with reduced and preserved ejection fraction. Methods and Results—: Thirteen biomarkers reflecting diverse pathophysiologic domains were examined in 8569 HF-free participants in Prevention of Vascular and Renal Endstage Disease (mean age, 49 years; 50% men). Subjects were categorized in 2 risk groups based on cardiovascular history. Incremental value per biomarker was assessed using Harrell C-indices. One hundred sixty-eight subjects (2.4%) were diagnosed with new-onset HF in the low-risk group (n=6915; Framingham Risk Score, 5.9%) and 206 (12.2%) subjects in the high-risk group (n=1654; Framingham Risk Score, 18.6%). The association of natriuretic peptides, adrenomedullin, endothelin, and galectin-3 with new-onset HF was stronger in the high-risk group (all P P <0.001) in the high-risk group. Except for a modest effect of cystatin-C, no biomarker was associated with increased risk for HF with preserved ejection fraction. Conclusions—: Risk stratification increases the incremental value per biomarker to predict new-onset HF, especially HF with reduced ejection fraction. We suggest that routine biomarker testing should be limited to the use of natriuretic peptides and troponin-T in patients with increased cardiovascular risk.Keywords
This publication has 45 references indexed in Scilit:
- Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the CommunityJACC, 2012
- Comparing New Onset Heart Failure with Reduced Ejection Fraction and New Onset Heart Failure with Preserved Ejection Fraction: An Epidemiologic PerspectiveCurrent Heart Failure Reports, 2012
- Differences in Biomarkers in Patients With Heart Failure With a Reduced vs a Preserved Left Ventricular Ejection FractionCanadian Journal of Cardiology, 2012
- Advances in the Epidemiology of Heart Failure and Left Ventricular RemodelingCirculation, 2011
- Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting With Acute DyspneaJACC, 2011
- Assessment of Conventional Cardiovascular Risk Factors and Multiple Biomarkers for the Prediction of Incident Heart Failure and Atrial FibrillationJACC, 2010
- Multimarker Approach for the Prediction of Heart Failure Incidence in the CommunityCirculation, 2010
- The Heart Failure EpidemicInternational Journal of Environmental Research and Public Health, 2010
- Resistin, Adiponectin, and Risk of Heart FailureJACC, 2009
- Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fractionJACC, 2004